🔗 Share this article WHO Sounds Alert Over Critical Scarcity of Obesity Jabs Less than one in 10 people who could benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it releases its initial advice on the drugs. Given over a billion people worldwide currently living with obesity, it is calling for broader and more equitable availability to these injectable treatments. Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "The new guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and distribution challenges are key barriers to broad availability to the injections that can aid individuals in losing substantial body mass, says the agency. Weight-Loss Drug Scarcity Even in the present most optimistic case, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of those who need them, per the WHO. The recommendation encourages nations and manufacturers to increase access, by measures like licensing agreements. A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026. The Way Weight-Loss Jabs Work The injections replicate a body's own hormone to slow digestion, curb appetite and boost feelings of fullness so individuals consume fewer calories. People typically see weight reduction within a few weeks of beginning the once-weekly jabs. Evidence indicates people may regain a significant portion after a year of stopping the treatment, as their normal appetite resume. To be above a healthy weight increases your likelihood for contracting diseases, including diabetes, cardiovascular issues, stroke, and specific cancers. Obesity affects people in every country and was responsible for millions of fatalities worldwide in 2024, as per the WHO.
Less than one in 10 people who could benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it releases its initial advice on the drugs. Given over a billion people worldwide currently living with obesity, it is calling for broader and more equitable availability to these injectable treatments. Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "The new guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and distribution challenges are key barriers to broad availability to the injections that can aid individuals in losing substantial body mass, says the agency. Weight-Loss Drug Scarcity Even in the present most optimistic case, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of those who need them, per the WHO. The recommendation encourages nations and manufacturers to increase access, by measures like licensing agreements. A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026. The Way Weight-Loss Jabs Work The injections replicate a body's own hormone to slow digestion, curb appetite and boost feelings of fullness so individuals consume fewer calories. People typically see weight reduction within a few weeks of beginning the once-weekly jabs. Evidence indicates people may regain a significant portion after a year of stopping the treatment, as their normal appetite resume. To be above a healthy weight increases your likelihood for contracting diseases, including diabetes, cardiovascular issues, stroke, and specific cancers. Obesity affects people in every country and was responsible for millions of fatalities worldwide in 2024, as per the WHO.